43.45
-0.73(-1.65%)
Currency In USD
| Previous Close | 44.18 |
| Open | 43.93 |
| Day High | 44.81 |
| Day Low | 43.05 |
| 52-Week High | 44.81 |
| 52-Week Low | 10.91 |
| Volume | 604,850 |
| Average Volume | 748,485 |
| Market Cap | 2.62B |
| PE | -33.17 |
| EPS | -1.31 |
| Moving Average 50 Days | 33.41 |
| Moving Average 200 Days | 22.2 |
| Change | -0.73 |
If you invested $1000 in Spyre Therapeutics, Inc. (SYRE) since IPO date, it would be worth $177.89 as of February 25, 2026 at a share price of $43.45. Whereas If you bought $1000 worth of Spyre Therapeutics, Inc. (SYRE) shares 5 years ago, it would be worth $235.18 as of February 25, 2026 at a share price of $43.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
GlobeNewswire Inc.
3 hours ago
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel di
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
WALTHAM, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel di
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
“6 in ’26” expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete ahead of schedule; Part A readouts accelerated, now